Abstract:SUMMARY:Aim: The aim of the present report was to investigate the probable association of circulating levels of PAI‐1 and expression of PAI‐1 in internal iliac artery walls with atherosclerotic disease in chronic haemodialysis (HD) patients.Methods: Sixty‐eight non‐diabetic HD patients and 50 age‐ and sex‐matched healthy normotensive controls participated in the study. Atherosclerotic disease in both groups was assessed by measuring intima‐media thickness (IMT) and plaque score of the common carotid arteries using an ultrasound scanner. Levels of serum PAI‐1, C‐reactive protein (CRP), interleukin (IL)‐6 and lipids profile were measured. Internal iliac artery samples were obtained at the time of renal transplantation. Quantitative expression of PAI‐1 in internal iliac artery walls was assessed by positive unit (pu) value using an immunohistochemical method. In addition, the IMT and carotid plaque score were analyzed in relation to circulating levels of PAI‐1 and expression of PAI‐1 in internal iliac artery walls.Results: Compared with control subjects, HD patients had significantly increased common carotid artery (CCA)‐IMT (P = 0.002). Atherosclerotic plaques were detected in 42 (61.76%) of HD patients and in two (4%) controls. The above ultrasonographic indices were correlated with age in HD patients (P < 0.001). A significant relationship was observed between IMT and systolic blood pressure (BP), low‐density lipoprotein in HD patients (P < 0.001 and P < 0.001, respectively). In HD patients, IMT was significantly correlated with CRP and IL‐6 (P < 0.001 and P < 0.001, respectively). In HD patients, a close correlation was found between serum PAI‐1 level, CRP and IL‐6 (P < 0.01 and P < 0.01, respectively). A close correlation was also found between PAI‐1 pu value, CRP and IL‐6 (P < 0.01 and P < 0.01 respectively). Serum PAI‐1 level is highly correlated to PAI‐1 pu value (P < 0.01). In HD patients, CCA‐IMT and plaque score were correlated significantly with circulating levels of PAI‐1(P < 0.01 and P < 0.05, respectively) and expression of PAI‐1 in internal iliac artery walls (P < 0.01 and P < 0.05, respectively). Multivariate analysis showed that log CRP values were a strong independent contributor to CCA‐IMT and plaque score (P = 0.03 and P = 0.04, respectively). Multivariate analysis showed that serum PAI‐1 concentration was a strong independent correlate of CCA‐IMT and carotid plaque score (P = 0.004 and P = 0.009, respectively). Multivariate analysis also showed that expression of PAI‐1 in internal iliac artery walls was a strong independent correlate of CCA‐IMT and carotid plaque score (P = 0.008 and P = 0.005, respectively).Conclusion: The circulating levels of PAI‐1 and expression of PAI‐1 in internal iliac artery walls were statistically associated with CRP, IL‐6 and low‐density lipoprotein cholesterol. Moreover, in HD patients, CCA‐IMT and plaque score were correlated significantly with circulating levels of PAI‐1 and expression of PAI‐1 in internal iliac artery walls and the circulating levels of PAI‐1 and expression of PAI‐1 in internal iliac artery walls were independent predictors of carotid atherosclerosis including CCA‐IMT and carotid plaque score. The correlations may suggest that increased circulating PAI‐1 level and upregulated expression of PAI‐1 in the vasculature could indicate a chronic endothelium activated state and PAI‐1 may more precisely identify the risk of atherothrombosis and be useful as a target for anti‐inflammatory treatment strategies.

Plasminogen activator inhibitor-1 reduces cardiac fibrosis and promotes M2 macrophage polarization in inflammatory cardiomyopathy

Abstract 11929: PAI-1 is Cardioprotective in Human Inflammatory Cardiomyopathy

P6450Plasminogen activator inhibitor type-1 (PAI-1) expression relates to the presence of myocardial inflammation in patients with nonischemic cardiomyopathy

Phosphatase PPM1L Prevents Excessive Inflammatory Responses and Cardiac Dysfunction after Myocardial Infarction by Inhibiting IKKβ Activation.

PAI-1 (Plasminogen Activator Inhibitor-1) Expression Renders Alternatively Activated Human Macrophages Proteolytically Quiescent

Abstract 659: Plasminogen Activator Inhibitor-1 (PAI-1) Increases Mitochondrial Membrane Potential In Vascular Smooth Muscle Cells And Coronary Arteries

Vascular Endothelial S1pr1 Ameliorates Adverse Cardiac Remodelling Via Stimulating Reparative Macrophage Proliferation after Myocardial Infarction.

PAI-1 Regulates the Cytoskeleton and Intrinsic Stiffness of Vascular Smooth Muscle Cells

The Role of Plasminogen Activator Inhibitor Type-1 in Fibrosis

Drug Targeting of Plasminogen Activator Inhibitor-1 Inhibits Metabolic Dysfunction and Atherosclerosis in a Murine Model of Metabolic Syndrome

Plasminogen activator Inhibitor-2 inhibits pulmonary arterial smooth muscle cell proliferation in pulmonary arterial hypertension via PI3K/Akt and ERK signaling

C-Reactive Protein Promotes Cardiac Inflammation and Fibrosis in Angiotensin Ii-Induced Hypertensive Cardiovascular Diseases

Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition

Pharmacological Targeting of Plasminogen Activator Inhibitor-1 Decreases Vascular Smooth Muscle Cell Migration and Neointima Formation

Abstract 606: Pharmacological Inhibition of PAI-1 Rescues Blood Flow Perfusion Through Promoting Capillary Arterialization in Diabetic Microangiopathy in Ischemic Limb

A Serpin With a Finger in Many PAIs: PAI-1's Central Function in Thromboinflammation and Cardiovascular Disease

Plasminogen Activator Inhibitor-1 Promotes the Recruitment and Polarization of Macrophages in Cancer

Recombinant Plasminogen Activator Inhibitor-1 Inhibits Intimal Hyperplasia

PAI-1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA

Atherosclerosis is Associated with Plasminogen Activator Inhibitor Type-1 in Chronic Haemodialysis Patients

Protease-activated Receptor 2 Deficiency in Hematopoietic Lineage Protects Against Myocardial Infarction Through Attenuated Inflammatory Response and Fibrosis.